Session » Systemic Lupus Erythematosus - Clinical Aspects and Treatment VI: Novel Therapies
- 4:30PM-6:00PM
-
Abstract Number: 3218
A Randomized, Double-Blind, Placebo-Controlled, 52-Week Study of the Efficacy and Safety of Belimumab Administered Subcutaneously Plus Standard Care to Patients with Systemic Lupus Erythematosus (SLE)
- 4:30PM-6:00PM
-
Abstract Number: 3220
Anifrolumab Differentially Suppresses Peripheral Biomarkers of Systemic Lupus Erythematosus Compared with Placebo in a Phase IIb Trial
- 4:30PM-6:00PM
-
Abstract Number: 3223
Anifrolumab, an Anti-Interferon Alpha Receptor Monoclonal Antibody, in Moderate to Severe Systemic Lupus Erythematosus (SLE)
- 4:30PM-6:00PM
-
Abstract Number: 3219
Efficacy and Safety of 4 Weeks Administration of Arsenic Trioxide in Moderate Active Systemic Lupus Erythematosus. a Phase I/II Proof-of-Concept Sequential Dose Escalation Multicenter Study
- 4:30PM-6:00PM
-
Abstract Number: 3222
Repeated Administration of Dapirolizumab Pegol (DZP) Appears Safe and Well Tolerated in Patients with Systemic Lupus Erythematosus (SLE) and Is Accompanied By an Improvement in Disease Activity: Results from a Phase 1 Study
- 4:30PM-6:00PM
-
Abstract Number: 3221
Safety and Efficiency of Low-Dose Interleukin-2 Treatment in Systemic Lupus Erythematosus